Advice
Following a resubmission
imiquimod (Aldara) is accepted for restricted use within NHS Scotland for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. It should be restricted to use in patients after specialist advice.
Imiquimod was more effective than vehicle in clearing actinic keratosis lesions.
Download detailed advice86KB (PDF)
Medicine details
- Medicine name:
- imiquimod 5% cream (Aldara)
- SMC ID:
- 385/07
- Indication:
- Topical treatment of actinic keratoses
- Pharmaceutical company
- Meda Pharmaceuticals Ltd
- BNF chapter
- Skin
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 12 May 2008